These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 17573817)
41. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? Rajakulendran S; Gadsby K; Deighton C Musculoskeletal Care; 2008 Dec; 6(4):233-45. PubMed ID: 18702106 [TBL] [Abstract][Full Text] [Related]
44. Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis. Suarez-Almazor ME; Berrios-Rivera JP; Cox V; Janssen NM; Marcus DM; Sessoms S J Rheumatol; 2007 Dec; 34(12):2400-7. PubMed ID: 17985405 [TBL] [Abstract][Full Text] [Related]
45. Health-related quality of life in rheumatoid arthritis patients in South India. Mathew AJ; Antony J; Eremenco S; Paul BV; Jayakumar B; Philip J Singapore Med J; 2009 Aug; 50(8):800-3. PubMed ID: 19710980 [TBL] [Abstract][Full Text] [Related]
46. Rheumatology practice in Japan: challenges and opportunities. Oku K; Atsumi T Rheumatol Int; 2019 Sep; 39(9):1499-1505. PubMed ID: 30888472 [TBL] [Abstract][Full Text] [Related]
47. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis. O'Dell JR Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):457-61. PubMed ID: 20732644 [TBL] [Abstract][Full Text] [Related]
48. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454 [TBL] [Abstract][Full Text] [Related]
49. Efficacy of biologicals in the treatment of rheumatoid arthritis. a meta-analysis. Venkateshan SP; Sidhu S; Malhotra S; Pandhi P Pharmacology; 2009; 83(1):1-9. PubMed ID: 18957873 [TBL] [Abstract][Full Text] [Related]
50. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T; Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945 [TBL] [Abstract][Full Text] [Related]
51. Some principles of the development of a clinical database/national register of selected inflammatory rheumatic diseases in the Czech Republic. Dostal C; Pavelka K; Zvárová J; Hanzlícek P; Olejárová M Int J Med Inform; 2006; 75(3-4):216-23. PubMed ID: 16169767 [TBL] [Abstract][Full Text] [Related]
52. Early rheumatoid arthritis -- is there a window of opportunity? Cush JJ J Rheumatol Suppl; 2007 Nov; 80():1-7. PubMed ID: 17985417 [TBL] [Abstract][Full Text] [Related]
53. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459 [TBL] [Abstract][Full Text] [Related]
54. Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. Nyberg F; Askling J; Berglind N; Franzén S; Ho M; Holmqvist M; Horne L; Lampl K; Michaud K; Pappas DA; Reed G; Symmons D; Tanaka E; Tran TN; Verstappen SM; Wesby-van Swaay E; Yamanaka H; Greenberg JD Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1121-32. PubMed ID: 26303866 [TBL] [Abstract][Full Text] [Related]
55. The role of biologicals in early rheumatoid arthritis. Haque UJ; Bathon JM Best Pract Res Clin Rheumatol; 2005 Feb; 19(1):179-89. PubMed ID: 15588978 [TBL] [Abstract][Full Text] [Related]
56. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Yazici Y; Shi N; John A Bull NYU Hosp Jt Dis; 2008; 66(2):77-85. PubMed ID: 18537774 [TBL] [Abstract][Full Text] [Related]
57. Effectiveness of an integrated outpatient care programme compared with present-day standard care in early rheumatoid arthritis. Esselens G; Westhovens R; Verschueren P Musculoskeletal Care; 2009 Mar; 7(1):1-16. PubMed ID: 18618520 [TBL] [Abstract][Full Text] [Related]
58. Biologic therapy for early rheumatoid arthritis: the latest evidence. Castro-Rueda H; Kavanaugh A Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524 [TBL] [Abstract][Full Text] [Related]
59. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme? Lu CY; Williams KM; Day RO Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999 [TBL] [Abstract][Full Text] [Related]
60. Korean Observational Study Network for Arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. Sung YK; Cho SK; Choi CB; Park SY; Shim J; Ahn JK; Bang SY; Cha HS; Choe JY; Chung WT; Her M; Hong SJ; Hong YK; Joung CI; Jun JB; Jung YO; Kang YM; Kim DY; Kim HR; Kim HA; Kim J; Kim SK; Kim SI; Kim TH; Kim TJ; Koh E; Lee CK; Lee HS; Lee J; Lee SH; Lee SH; Lee SS; Lee SW; Lee YA; Nah SS; Park SH; Sheen DH; Shim SC; Gyu Song G; Suh CH; Uhm WS; Yoo DH; Yoo WH; Yoon BY; Bae SC Semin Arthritis Rheum; 2012 Jun; 41(6):745-51. PubMed ID: 22154221 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]